[Individual outcome monitoring of TSH receptor antibody level for predicting the prognosis of Graves' disease].
This retrospective study is intended to provide further information on the controversially discussed ability of a Thyrotropin Receptor Antibody (TRAb) monitoring for predicting the outcome of Graves' disease. The study is based on 1480 blood samples of 346 patients (292 female, 54 male; age among 9 and 91 years) suffering from Graves' disease. A comparison between the TRAb levels and the serum free thyroid hormones as well as the basal thyrotropin was performed in the entire collective, in the group of non-treated patients and in 182 individual courses. Even in comparable states of function, the individual TRAb levels were quite divergent. In the group with persistent dysfunction, they initially varied between 6 and 482 U/l (normal range < 15 U/l). A global evaluation of the particular groups hence did not show any correlation between the functional disorder and the respective TRAb levels. However, when considering the individual courses, a distinct dependence upon the development of the TRAb could be observed. As the limit for separating the group suffering from persistent malfunction or recurrence and the collective in remission, a decline of the individual TRAb level below 50% of the initial value has proven to be most suitable. This was observed in 94% of all remissions. In 90% of all relapsed patients, we either found persistent high TRAb levels (i.e. a maximum decrease down to 50% of the initial value) or another increase of the TRAb levels. The positive and negative predictive values of the method are 97% and 58%, respectively. The outcome of Graves' disease depends on the individual changes of the TRAb levels rather than on their absolute values. In case of persistent TRAb, you have to expect a continuing dysfunction or a recurrence.